Altimmune (NASDAQ:ALT) Posts Earnings Results

Altimmune (NASDAQ:ALT) released its quarterly earnings results on Thursday. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.08, Zacks reports. The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.00 million. Altimmune had a negative return on equity of 62.63% and a negative net margin of 438,730.03%.

Altimmune Stock Performance

Shares of ALT traded up $0.17 during trading hours on Friday, reaching $4.11. 4,196,187 shares of the company traded hands, compared to its average volume of 3,502,033. The company has a debt-to-equity ratio of 0.09, a quick ratio of 20.44 and a current ratio of 20.44. The stock’s fifty day moving average is $3.87 and its 200 day moving average is $4.54. Altimmune has a 1-year low of $2.90 and a 1-year high of $11.16. The stock has a market cap of $362.74 million, a P/E ratio of -3.48 and a beta of 0.01.

Analyst Ratings Changes

Several equities research analysts recently weighed in on ALT shares. HC Wainwright restated a “buy” rating and issued a $12.00 target price on shares of Altimmune in a report on Monday, October 20th. UBS Group reduced their price objective on shares of Altimmune from $26.00 to $24.00 and set a “buy” rating for the company in a research note on Wednesday, August 13th. B. Riley decreased their price objective on shares of Altimmune from $20.00 to $18.00 and set a “buy” rating for the company in a report on Wednesday, August 13th. Citizens Jmp lowered their target price on shares of Altimmune from $15.00 to $14.00 and set a “market outperform” rating on the stock in a research note on Friday. Finally, Wall Street Zen raised shares of Altimmune from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Altimmune currently has an average rating of “Hold” and a consensus target price of $16.83.

Hedge Funds Weigh In On Altimmune

Several large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in shares of Altimmune by 23.3% in the 3rd quarter. Vanguard Group Inc. now owns 6,373,638 shares of the company’s stock worth $24,029,000 after acquiring an additional 1,206,514 shares during the period. B. Riley Wealth Advisors Inc. bought a new position in Altimmune in the second quarter worth $71,000. Headlands Technologies LLC acquired a new stake in Altimmune during the second quarter worth $72,000. Tower Research Capital LLC TRC increased its holdings in Altimmune by 234.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 14,956 shares of the company’s stock valued at $58,000 after buying an additional 10,490 shares during the period. Finally, BNP Paribas Financial Markets increased its holdings in Altimmune by 108.5% in the 2nd quarter. BNP Paribas Financial Markets now owns 10,095 shares of the company’s stock valued at $39,000 after buying an additional 5,253 shares during the period. Institutional investors and hedge funds own 78.05% of the company’s stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.